Akari Therapeutics (AKTX) Competitors $1.24 -0.06 (-4.59%) Closing price 05/21/2025 03:53 PM EasternExtended Trading$1.24 0.00 (0.00%) As of 04:03 AM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more. Add Compare Share Share Competitors Stock AnalysisChartCompetitorsHeadlinesSEC FilingsShort InterestTrendsBuy This Stock AKTX vs. PLX, TARA, FTLF, RAPT, ENTA, ATOS, ALEC, EDIT, EXOZ, and LRMRShould you be buying Akari Therapeutics stock or one of its competitors? The main competitors of Akari Therapeutics include Protalix BioTherapeutics (PLX), Protara Therapeutics (TARA), FitLife Brands (FTLF), RAPT Therapeutics (RAPT), Enanta Pharmaceuticals (ENTA), Atossa Therapeutics (ATOS), Alector (ALEC), Editas Medicine (EDIT), Exozymes (EXOZ), and Larimar Therapeutics (LRMR). These companies are all part of the "pharmaceutical products" industry. Akari Therapeutics vs. Protalix BioTherapeutics Protara Therapeutics FitLife Brands RAPT Therapeutics Enanta Pharmaceuticals Atossa Therapeutics Alector Editas Medicine Exozymes Larimar Therapeutics Protalix BioTherapeutics (NYSE:PLX) and Akari Therapeutics (NASDAQ:AKTX) are both small-cap medical companies, but which is the superior stock? We will compare the two businesses based on the strength of their risk, valuation, institutional ownership, community ranking, earnings, profitability, dividends, media sentiment and analyst recommendations. Does the MarketBeat Community favor PLX or AKTX? Akari Therapeutics received 249 more outperform votes than Protalix BioTherapeutics when rated by MarketBeat users. However, 81.25% of users gave Protalix BioTherapeutics an outperform vote while only 49.53% of users gave Akari Therapeutics an outperform vote. CompanyUnderperformOutperformProtalix BioTherapeuticsOutperform Votes1381.25% Underperform Votes318.75%Akari TherapeuticsOutperform Votes26249.53% Underperform Votes26750.47% Which has better valuation & earnings, PLX or AKTX? Protalix BioTherapeutics has higher revenue and earnings than Akari Therapeutics. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioProtalix BioTherapeutics$59.76M2.28$8.31M$0.0442.75Akari TherapeuticsN/AN/A-$10.01MN/AN/A Do insiders and institutionals hold more shares of PLX or AKTX? 16.5% of Protalix BioTherapeutics shares are owned by institutional investors. Comparatively, 5.1% of Akari Therapeutics shares are owned by institutional investors. 6.5% of Protalix BioTherapeutics shares are owned by insiders. Comparatively, 38.9% of Akari Therapeutics shares are owned by insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a stock is poised for long-term growth. Is PLX or AKTX more profitable? Akari Therapeutics has a net margin of 0.00% compared to Protalix BioTherapeutics' net margin of -21.03%. Akari Therapeutics' return on equity of 0.00% beat Protalix BioTherapeutics' return on equity.Company Net Margins Return on Equity Return on Assets Protalix BioTherapeutics-21.03% -30.89% -11.74% Akari Therapeutics N/A N/A N/A Which has more risk and volatility, PLX or AKTX? Protalix BioTherapeutics has a beta of -0.05, suggesting that its stock price is 105% less volatile than the S&P 500. Comparatively, Akari Therapeutics has a beta of 0.29, suggesting that its stock price is 71% less volatile than the S&P 500. Does the media favor PLX or AKTX? In the previous week, Protalix BioTherapeutics had 4 more articles in the media than Akari Therapeutics. MarketBeat recorded 7 mentions for Protalix BioTherapeutics and 3 mentions for Akari Therapeutics. Protalix BioTherapeutics' average media sentiment score of 0.16 beat Akari Therapeutics' score of -0.48 indicating that Protalix BioTherapeutics is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Protalix BioTherapeutics 0 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral Akari Therapeutics 0 Very Positive mention(s) 0 Positive mention(s) 2 Neutral mention(s) 1 Negative mention(s) 0 Very Negative mention(s) Neutral Do analysts prefer PLX or AKTX? Protalix BioTherapeutics currently has a consensus target price of $15.00, indicating a potential upside of 777.19%. Given Protalix BioTherapeutics' stronger consensus rating and higher possible upside, research analysts plainly believe Protalix BioTherapeutics is more favorable than Akari Therapeutics.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Protalix BioTherapeutics 0 Sell rating(s) 0 Hold rating(s) 1 Buy rating(s) 0 Strong Buy rating(s) 3.00Akari Therapeutics 0 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 0.00 SummaryProtalix BioTherapeutics beats Akari Therapeutics on 9 of the 15 factors compared between the two stocks. Get Akari Therapeutics News Delivered to You Automatically Sign up to receive the latest news and ratings for AKTX and its competitors with MarketBeat's FREE daily newsletter. Email Address New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding {thisCompany.Symbol} and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart AKTX vs. The Competition Export to ExcelMetricAkari TherapeuticsPharmaceutical IndustryMedical SectorNASDAQ ExchangeMarket Cap$32.98M$6.52B$5.37B$8.39BDividend YieldN/A2.65%5.21%4.10%P/E RatioN/A8.9226.8219.71Price / SalesN/A252.24388.85117.28Price / CashN/A65.8538.2534.62Price / Book-41.336.466.804.50Net Income-$10.01M$143.98M$3.23B$248.18M7 Day Performance-6.06%2.03%1.53%0.20%1 Month Performance-8.82%4.11%10.05%12.37%1 Year Performance-35.08%-2.87%16.76%7.04% Akari Therapeutics Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)AKTXAkari TherapeuticsN/A$1.24-4.6%N/A-24.2%$32.98MN/A0.009Analyst ForecastGap DownPLXProtalix BioTherapeutics2.1884 of 5 stars$1.68+0.6%$15.00+792.9%+40.2%$133.74M$59.76M-12.92200TARAProtara Therapeutics2.1908 of 5 stars$3.42+7.2%$20.40+496.5%+10.9%$131.95MN/A-1.2130Positive NewsGap UpFTLFFitLife Brands4.4274 of 5 stars$13.79+1.1%$20.50+48.7%+0.0%$129.41M$64.47M16.3220Earnings ReportRAPTRAPT Therapeutics4.3876 of 5 stars$0.97+15.4%$4.00+313.3%-80.7%$128.04M$1.53M-0.3580Positive NewsGap DownENTAEnanta Pharmaceuticals3.8091 of 5 stars$5.96+3.7%$17.25+189.4%-53.6%$127.41M$64.46M-1.20160ATOSAtossa Therapeutics1.8417 of 5 stars$0.98+1.4%$7.13+624.4%-46.6%$127.05MN/A-4.478ALECAlector3.7799 of 5 stars$1.27+4.1%$4.00+215.0%-76.8%$126.99M$88.34M-0.75270News CoverageEDITEditas Medicine4.2645 of 5 stars$1.49-1.3%$5.36+260.0%-72.8%$124.73M$35.84M-0.58230Positive NewsGap UpEXOZExozymesN/A$14.90-0.9%N/AN/A$124.68MN/A0.0029Gap DownLRMRLarimar Therapeutics2.0685 of 5 stars$1.95-1.8%$19.63+909.0%-75.5%$124.53MN/A-1.6930 Related Companies and Tools Related Companies Protalix BioTherapeutics Competitors Protara Therapeutics Competitors FitLife Brands Competitors RAPT Therapeutics Competitors Enanta Pharmaceuticals Competitors Atossa Therapeutics Competitors Alector Competitors Editas Medicine Competitors Exozymes Competitors Larimar Therapeutics Competitors Top 10 Stock Comparisons Semiconductor Stocks Artificial Intelligence Stocks Growth Stocks Magnificent Seven Stocks Pharmaceutical Stocks Ecommerce Stocks Bitcoin Stocks Meme Stocks Cryptocurrency Stocks Cybersecurity Stocks This page (NASDAQ:AKTX) was last updated on 5/22/2025 by MarketBeat.com Staff From Our PartnersJuly 2025 Rule Change to Impact Retirement InvestorsThere's a massive change from a new rule going into effect this July. And it's one the Big Banks are alread...Premier Gold Co | SponsoredCollect $7k per month from Tesla’s SECRET dividendTesla doesn't pay a traditional dividend.... But I just discovered a secret backdoor to collect a secret 69...Investors Alley | SponsoredThe DOJ Just Said Your Money Isn’t YoursWhat If Washington Declared That: YOUR Money ISN'T Actually Yours? Sounds insane, but that's exactly what ...Priority Gold | SponsoredThe Prophet's Newest PredictionA storm is brewing in the markets: new tariffs, recession warnings, and panic in the headlines. That’s when pu...Stansberry Research | SponsoredA new financial chapter Porter Stansberry says what happened last week could become the defining legacy of his financial publishing ca...Porter & Company | SponsoredThe Secret Map of America, Declassified…Locked inside a Maryland man’s private safe is a map. But not just any map, mind you… This map shows a “...Banyan Hill Publishing | SponsoredTrump’s Bitcoin Reserve is No Accident…How everyday investors are building crypto wealth (step-by-step guide) Don't wait. The window for maximum g...Crypto 101 Media | SponsoredHow I profit during chaos…This Guy THRIVES on Chaos Wall Street legend Larry Benedict has thrived through every major market crash. I...Brownstone Research | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Akari Therapeutics, Plc Please log in to your account or sign up in order to add this asset to your watchlist. Share Akari Therapeutics With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Buy AKTX Stock Free AKTX Stock Alerts